ZVRA (Zevra Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

ZVRA (Zevra Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

ZVRAZevra Therapeutics, Inc.

Mkt Cap$618M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Revenue (TTM)$106M

Net Income (TTM)$83M

EPS (TTM)$1.50

Free Cash Flow (TTM)-$2M

Gross Margin84.5%

Op. Margin-59.1%

Net Margin78.2%

FCF Margin-2.3%

P/S Ratio (TTM)5.8x

P/E Ratio (TTM)7.4x

YoY Rev Growth+350.9%

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$3M	$3M	-$13M
Q2 23	$8M	$8M	-$6M
Q3 23	$3M	$3M	-$15M
Q4 23	$13M	$10M	-$15M
Q1 24	$3M	$160K	-$20M
Q2 24	$4M	$876K	-$24M
Q3 24	$4M	$1M	-$27M
Q4 24	$12M	$11M	-$15M
Q1 25	$20M	$19M	-$5M
Q2 25	$26M	$14M	-$71M
Q3 25	$26M	$25M	$4M
Q4 25	$34M	$33M	$9M

Revenue Breakdown

Valuation

Quarter	P/S	P/E
Q1 23	63.9x	—
Q2 23	36.7x	—
Q3 23	36.7x	—
Q4 23	22.3x	—
Q1 24	22.1x	—
Q2 24	25.8x	—
Q3 24	24.9x	—
Q4 24	26.2x	—
Q1 25	15.2x	—
Q2 25	10.0x	233.8x
Q3 25	7.3x	17.5x
Q4 25	5.8x	7.4x

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$4M	-$4M
Q2 23	-$9M	-$9M
Q3 23	-$5M	-$5M
Q4 23	-$16M	-$16M
Q1 24	-$16M	-$16M
Q2 24	-$19M	-$19M
Q3 24	-$18M	-$18M
Q4 24	-$16M	-$16M
Q1 25	-$8M	-$8M
Q2 25	-$4M	-$4M
Q3 25	$5M	$4M
Q4 25	$6M	$6M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$29K
Q2 23	$23K
Q3 23	$172K
Q4 23	$72K
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$99K
Q2 25	$213K
Q3 25	$554K
Q4 25	$31K

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	-19.9%	+174.8%
Q2 23	+551.5%	-43.5%
Q3 23	+0.7%	+92.2%
Q4 23	+469.9%	+141.0%
Q1 24	+7.8%	+49.4%
Q2 24	-47.5%	+91.8%
Q3 24	+27.6%	+69.8%
Q4 24	-8.9%	-1.5%
Q1 25	+495.6%	+7.7%
Q2 25	+481.7%	+243.2%
Q3 25	+605.4%	-29.3%
Q4 25	+183.4%	-9.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$945K	29.8%
Q2 23	$2M	25.4%
Q3 23	$1M	47.9%
Q4 23	$3M	22.4%
Q1 24	$2M	61.9%
Q2 24	$3M	59.2%
Q3 24	$6M	166.1%
Q4 24	$4M	33.4%
Q1 25	$3M	15.3%
Q2 25	$2M	9.5%
Q3 25	$3M	10.6%
Q4 25	$4M	12.6%

OpEx Breakdown

Quarter	R&D	G&A	S&M	SG&A
Q1 23	$9M	—	—	$7M
Q2 23	$7M	—	—	$7M
Q3 23	$12M	—	—	$6M
Q4 23	$10M	—	—	$15M
Q1 24	$11M	—	—	$10M
Q2 24	$11M	$2M	$11M	—
Q3 24	$11M	—	—	$16M
Q4 24	$10M	$2M	$15M	—
Q1 25	$3M	—	—	$20M
Q2 25	$3M	—	—	$21M
Q3 25	$3M	—	—	$17M
Q4 25	$3M	—	—	$20M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$40M	$55M	$95M
Q2 23	$66M	$21M	$87M
Q3 23	$43M	$40M	$83M
Q4 23	$43M	$25M	$68M
Q1 24	$43M	$10M	$53M
Q2 24	$39M	$10M	$49M
Q3 24	$54M	$35M	$89M
Q4 24	$34M	$36M	$69M
Q1 25	$37M	$25M	$63M
Q2 25	$48M	$155M	$203M
Q3 25	$54M	$145M	$200M
Q4 25	$62M	$0	$62M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	34M	-0.1%
Q2 23	34M	-1.6%
Q3 23	35M	+2.4%
Q4 23	38M	+9.1%
Q1 24	42M	+10.2%
Q2 24	42M	+0.3%
Q3 24	48M	+14.1%
Q4 24	54M	+12.3%
Q1 25	54M	+0.8%
Q2 25	56M	+4.1%
Q3 25	56M	-0.7%
Q4 25	57M	+2.3%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 14	—	—
FY 15	—	—
FY 16	—	—
FY 17	—	—
FY 18	—	—
FY 19	—	—
FY 20	—	—
FY 21	—	—
FY 22	—	—
FY 23	$398K	69
FY 24	$400K	59
FY 25	$53K	2K